Differential expression of CCN family members CYR611, CTGF and NOV in gastric cancer and their association with disease progression

Li,Jun; Gao,Xiangyu; Ji,Ke; Sanders,Andrew   J.; Zhang,Zhongtao; Jiang,Wen  G.; Ji,Jiafu; Ye,Lin

doi:10.3892/or.2016.5074

Differential expression of CCN family members CYR611, CTGF and NOV in gastric cancer and their association with disease progression

Authors:
- Jun Li
- Xiangyu Gao
- Ke Ji
- Andrew J. Sanders
- Zhongtao Zhang
- Wen G. Jiang
- Jiafu Ji
- Lin Ye
View Affiliations

Affiliations: Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases, Xi-Cheng, Beijing 100050, P.R. China, Cardiff China Medical Research Collaborative, Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK, Key Laboratory of Carcinogenesis and Translational Research (Chinese Ministry of Education), Department of GI Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: September 8, 2016 https://doi.org/10.3892/or.2016.5074
Pages: 2517-2525
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CCN is an acronym for cysteine-rich protein 61 (CYR61), connective tissue growth factor (CTGF) and nephroblastoma overexpressed (NOV). Aberrations of certain CCN members including CYR61, CTGF, Wnt1-inducible signalling pathway protein (WISP)-1 and -3 have been reported in gastric cancer. The present study aimed to examine the clinical relevance of NOV along with CYR61 and CTGF in gastric cancer by analysing their transcript levels. CYR61, CTGF and NOV transcript expression in 324 gastric cancer samples with paired adjacent normal gastric tissues were determined using real-time quantitative PCR and the results were statistically analysed against patient clinicopathological data using SPSS software. NOV mRNA levels in gastric cancer tissues were significantly elevated when compared with levels in their paired adjacent non-cancerous tissues. Local advanced tumours with invasive expansion (T3 and T4) expressed higher levels of NOV (p=0.013) compared with the less invasive tumours (T1 and T2). CYR61 transcript levels were also significantly increased in gastric cancers compared with levels in the adjacent non-cancerous tissues. Kaplan-Meier survival curves revealed that patients with CYR61-low transcript levels had longer overall survival (OS) (p=0.018) and disease-free survival (DFS) (p=0.015). NOV overexpression promoted the in vitro proliferation of AGS cells while the knockdown resulted in a reduced proliferation of HGC27 cells. A similar effect was observed for the invasion of these two gastric cancer cell lines. NOV expression was increased in gastric cancer which was associated with local invasion and distant metastases. Taken together, the expression of NOV and CYR61 was increased in gastric cancer. The elevated expression of CYR61 was associated with poorer survival. NOV promoted proliferation and invasion of gastric cancer cells. Further investigations may highlight their predictive and therapeutic potential in gastric cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Brock A, Krause S and Ingber DE: Control of cancer formation by intrinsic genetic noise and microenvironmental cues. Nat Rev Cancer. 15:499–509. 2015. View Article : Google Scholar : PubMed/NCBI
3	Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer. 9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI
4	Jia Q, Dong Q and Qin L: CCN: Core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma? Oncotarget. 7:1203–1214. 2016.
5	Chang CC, Lin BR, Wu TS, Jeng YM and Kuo ML: Input of microenvironmental regulation on colorectal cancer: Role of the CCN family. World J Gastroenterol. 20:6826–6831. 2014. View Article : Google Scholar : PubMed/NCBI
6	Riser BL, Barnes JL and Varani J: Balanced regulation of the CCN family of matricellular proteins: A novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal. 9:327–339. 2015. View Article : Google Scholar : PubMed/NCBI
7	Perbal B: CCN proteins: A centralized communication network. J Cell Commun Signal. 7:169–177. 2013. View Article : Google Scholar : PubMed/NCBI
8	Joliot A, Triller A, Volovitch M and Prochiantz A: Are embryonic forms of NCAM homeobox receptors? C R Acad Sci III. 314(Suppl 9): S59–S63. 1992.In French.
9	Kyurkchiev S, Yeger H, Bleau AM and Perbal B: Potential cellular conformations of the CCN3 (NOV) protein. Cell Commun Signal. 2:92004. View Article : Google Scholar
10	Desnoyers L: Structural basis and therapeutic implication of the interaction of CCN proteins with glycoconjugates. Curr Pharm Des. 10:3913–3928. 2004. View Article : Google Scholar : PubMed/NCBI
11	Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, et al: Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res. 11:7243–7254. 2005. View Article : Google Scholar : PubMed/NCBI
12	Lv H, Fan E, Sun S, Ma X, Zhang X, Han DM and Cong YS: Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. J Cell Biochem. 106:738–744. 2009. View Article : Google Scholar : PubMed/NCBI
13	Tsai MS, Hornby AE, Lakins J and Lupu R: Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 60:5603–5607. 2000.PubMed/NCBI
14	Ladwa R, Pringle H, Kumar R and West K: Expression of CTGF and Cyr61 in colorectal cancer. J Clin Pathol. 64:58–64. 2011. View Article : Google Scholar
15	Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer. 11:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
16	Lin BR, Chang CC, Chen RJ, Jeng YM, Liang JT, Lee PH, Chang KJ and Kuo ML: Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res. 17:3077–3088. 2011. View Article : Google Scholar : PubMed/NCBI
17	Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, Tong XJ and Xie D: Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem. 282:36571–36581. 2007. View Article : Google Scholar : PubMed/NCBI
18	Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, Feazell J, Yang GP, Koong A and Giaccia AJ: The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69:775–784. 2009. View Article : Google Scholar : PubMed/NCBI
19	Maillard M, Cadot B and Ball RY, Maillard M, Cadot B and Ball RY: Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol. 54:275–280. 2001. View Article : Google Scholar : PubMed/NCBI
20	Zhang T, Zhao C, Luo L, Xiang J, Sun Q, Cheng J and Chen D: The clinical and prognostic significance of CCN3 expression in patients with cervical cancer. Adv Clin Exp Med. 22:839–845. 2013.
21	Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ and Xie D: Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One. 2:e5342007. View Article : Google Scholar : PubMed/NCBI
22	Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM, Said JW and Koeffler HP: Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem. 279:53087–53096. 2004. View Article : Google Scholar : PubMed/NCBI
23	Maeta N, Osaki M, Shomori K, Inaba A, Kidani K, Ikeguchi M and Ito H: CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma. Oncology. 73:118–126. 2007. View Article : Google Scholar
24	Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, Kusuanco D, Marchevsky A, McKenna R and Koeffler HP: Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res. 4:591–598. 2006. View Article : Google Scholar : PubMed/NCBI
25	Bleau AM, Planque N, Lazar N, Zambelli D, Ori A, Quan T, Fisher G, Scotlandi K and Perbal B: Antiproliferative activity of CCN3: Involvement of the C-terminal module and post-translational regulation. J Cell Biochem. 101:1475–1491. 2007. View Article : Google Scholar : PubMed/NCBI
26	Thibout H, Martinerie C, Créminon C, Godeau F, Boudou P, Le Bouc Y and Laurent M: Characterization of human NOV in biological fluids: An enzyme immunoassay for the quantification of human NOV in sera from patients with diseases of the adrenal gland and of the nervous system. J Clin Endocrinol Metab. 88:327–336. 2003. View Article : Google Scholar : PubMed/NCBI
27	Tanaka S and Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y and Sugimachi K: A novel variant of WISP1 lacking a Von Mayebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene. 20:5525–5532. 2001. View Article : Google Scholar : PubMed/NCBI
28	Tanaka S, Sugimachi K, Maehara S, Shimada M and Maehara Y: A loss of function mutation in WISP3 derived from microsatellite unstable gastric carcinoma. Gastroenterology. 125:1563–1564. 2003. View Article : Google Scholar : PubMed/NCBI
29	Babic AM, Kireeva ML, Kolesnikova TV and Lau LF: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA. 95:6355–6360. 1998. View Article : Google Scholar : PubMed/NCBI
30	Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH, et al: Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res. 11:5809–5820. 2005. View Article : Google Scholar : PubMed/NCBI
31	Lin MT, Kuo IH, Chang CC, Chu CY, Chen HY, Lin BR, Sureshbabu M, Shih HJ and Kuo ML: Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion. J Biol Chem. 283:15807–15815. 2008. View Article : Google Scholar : PubMed/NCBI
32	Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE and Puntis MC: Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res. 55:5043–5048. 1995.PubMed/NCBI
33	Zuo GW, Kohls CD, He BC, Chen L, Zhang W, Shi Q, Zhang BQ, Kang Q, Luo J, Luo X, et al: The CCN proteins: Important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol. 25:795–806. 2010.PubMed/NCBI
34	Watari H, Xiong Y, Hassan MK and Sakuragi N: Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol. 112:229–234. 2009. View Article : Google Scholar
35	Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, et al: CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 68:7323–7331. 2008. View Article : Google Scholar : PubMed/NCBI
36	Wei J, Yu G, Shao G, Sun A, Chen M, Yang W and Lin Q: CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma. Oncotarget. Apr 20–2016.Epub ahead of print. View Article : Google Scholar
37	Liu L, Li Z, Feng G, You W and Li J: Expression of connective tissue growth factor is in agreement with the expression of VEGF, VEGF-C, -D and associated with shorter survival in gastric cancer. Pathol Int. 57:712–718. 2007. View Article : Google Scholar : PubMed/NCBI
38	Liu LY, Han YC, Wu SH and Lv ZH: Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer. World J Gastroenterol. 14:2110–2114. 2008. View Article : Google Scholar : PubMed/NCBI
39	Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN, Li YS, Wang CY, Zhang HY, Sun Z and Xu HM: Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer. 10:1222011. View Article : Google Scholar : PubMed/NCBI
40	Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K and Okada Y: Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16:219–221. 2002.
41	Sin WC, Bechberger JF, Rushlow WJ and Naus CC: Dose-dependent differential upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein Connexin43 in glioma cells. J Cell Biochem. 103:1772–1782. 2008. View Article : Google Scholar
42	Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B and Herlyn M: Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene. 27:2552–2560. 2008. View Article : Google Scholar